Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
Otsuka Holdings plans to boost its annual sales up to 2.5 trillion yen by FY2028, an increase of 480 billion yen compared to FY2023 results. While the company will face the expiration of patents for two of its mainstay products…
To read the full story
Related Article
- Otsuka Pharma Sales Rise 7.1% in 2025, Driven by Rexulti
February 16, 2026
- Otsuka Accelerates Pipeline Investment Centered on “Next 8” as Growth Drivers
August 1, 2025
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
BUSINESS
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Daiichi Sankyo Chair Manabe to Step Down in June
February 27, 2026
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…